drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic natural killer (NK) cells derived from cord blood and engineered with a chimeric antigen receptor targeting CD19 to mediate NK cytotoxicity (perforin/granzyme) against CD19-positive B-cell malignancies, with low risk of GVHD/CRS.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic cord blood–derived natural killer cells genetically engineered with a CD19-directed chimeric antigen receptor. CAR engagement of CD19 on malignant B cells triggers NK activation and perforin/granzyme-mediated cytotoxicity, with low risk of graft-versus-host disease and typically reduced cytokine release compared with CAR-T cells.
drug_name
Cord blood-derived CD19 CAR-NK
nct_id_drug_ref
NCT06464861